– USA, CA – ChromaCode, Inc., a pioneering genomics multiplexing platform company developing accessible and affordable laboratory-based solutions, today announced CEO Mark McDonough to the additional role of Chair of the Board of Directors effective January 1, 2024, succeeding Dr. Carol Gallagher who retired.
The company also announced the appointment of Dr. Michele Park (Ph.D.) to the Board of Directors.
“It is with great pleasure that we welcome Michele as the newest addition to our Board of Directors. She brings a wealth of expertise and a distinguished track record that will undoubtedly enrich our strategic discussions and decision-making processes. As we navigate the dynamic landscape of our industry, her insights and proven leadership will play a pivotal role in shaping the future of our company” said CEO and Chair, Mark McDonough.
About Dr. Michele Park
Michele Park is a Partner at NEA. Dr. Park has extensive experience in venture capital and life sciences investment. Before joining NEA, she worked as an investor at Clarus Ventures and served as a biotechnology research analyst at Credit Suisse and Piper Jaffray.
Dr. Park earned her Ph.D. in Molecular Biology from Weill Cornell Graduate School of Medical Sciences, conducting her dissertation at Memorial Sloan-Kettering Cancer Center. She holds a B.A. in Molecular Biology from Princeton University. Currently, Dr. Park serves as Vice Chair of the Cancer Prevention and Research Institute of Texas Product Development Advisory Committee.
About ChromaCode
ChromaCode is an innovator in genomics multiplexing platform technology, providing laboratory solutions with its proven HDPCR technology. HDPCR is a revolutionary approach allowing for deep multiplexing of biomarkers in a single, rapid, cost-effective assay for multiple sample types on standard laboratory dPCR platforms. This adaptable technology, deployed with ChromaCode’s cloud-based analysis, enables laboratories worldwide to affordably conduct testing internally and produce high-quality results with demonstrated high concordance with next-generation sequencing-based testing, increasing accessibility of diagnostics with a cost-effective and scalable solution.
SOURCE: https://chromacode.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
